HPLC in FDA Warning Letters
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
In the current compilation of Warning Letters issued between 2009 and 2011 we have summarised for you the key points regarding the use of high performance liquid chromatography (HPLC).
The inspection focuses can be summarised and compiled in the following 4 themes:
- Raw Data / Protection of Electronic Records
- Calibration / Qualification
- Method Validation
- System Suitability / Sequences
Author:
Dr Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


